Apafant

Apafant (WEB-2086, LSM-2613) is a drug which acts as a potent and selective inhibitor of the phospholipid mediator platelet-activating factor (PAF). It was developed by structural modification of the thienotriazolodiazepine sedative drug brotizolam and demonstrated that PAF inhibitory actions could be separated from activity at the benzodiazepine receptor. Apafant was investigated for several applications involving inflammatory responses such as asthma and conjunctivitis but was never adopted for medical use, however it continues to be used in pharmacology research.^[1][2][3][4]

Apafant

Identifiers
IUPAC name 3-(4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-yl)-1-(4-morpholinyl)-1-propanone
CAS Number	105219-56-5
PubChem CID	65889
IUPHAR/BPS	1859
ChemSpider	59298
UNII	J613NI05SV
KEGG	D01652
ChEBI	CHEBI:92490
ChEMBL	ChEMBL280164
CompTox Dashboard (EPA)	DTXSID5048974
ECHA InfoCard	100.220.442
Chemical and physical data
Formula	C22H22ClN5O2S
Molar mass	455.96 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=NN=C2N1C3=C(C=C(S3)CCC(=O)N4CCOCC4)C(=NC2)C5=CC=CC=C5Cl
InChI InChI=1S/C22H22ClN5O2S/c1-14-25-26-19-13-24-21(16-4-2-3-5-18(16)23)17-12-15(31-22(17)28(14)19)6-7-20(29)27-8-10-30-11-9-27/h2-5,12H,6-11,13H2,1H3 Key:JGPJQFOROWSRRS-UHFFFAOYSA-N